Autologous adipose derived stem cells ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04170426 (ClinicalTrials.gov) | December 2021 | 18/11/2019 | Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis | Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) | Rheumatoid Arthritis | Biological: autologous adipose derived stem cells | Celltex Therapeutics Corporation | NULL | Not yet recruiting | 18 Years | 75 Years | All | 54 | Phase 1/Phase 2 | NULL |